CNBC: Actavis swoops in on Allergan for Salix buyout talks

Talk about a love triangle. Actavis ($ACT) made an advance toward Allergan ($AGN) last month, which the latter spurned because it thought it was close to landing Salix ($SLXP). Now, sources tell CNBC that Actavis has swooped in on Salix, with deal talks ongoing. Report

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

The Tecentriq-Avastin-chemo cocktail did slightly better in PD-L1-positive patients but still failed to cross the statistical significance bar.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.